1 – 29 of 29
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Treatment for Rheumatoid Arthritis Associated With Alterations in the Gastrointestinal Microbiota
2024) In ACR Open Rheumatology(
- Contribution to journal › Article
-
Mark
Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice
(
- Contribution to journal › Article
-
Mark
Persistent pain and its predictors after starting anti-tumour necrosis factor therapy in psoriatic arthritis : what is the role of inflammation control?
(
- Contribution to journal › Article
-
Mark
Joint tenderness at 3 months follow-up better predicts long-term pain than baseline characteristics in early rheumatoid arthritis patients
(
- Contribution to journal › Article
- 2023
-
Mark
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: Data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness analysis of bimekizumab for the treatment of active psoriatic arthritis in Sweden
(
- Contribution to journal › Article
-
Mark
How good is the agreement between clinical diagnoses and classification criteria fulfilment in axial spondyloarthritis? Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
-
Mark
Methotrexate treatment in early psoriatic arthritis in comparison to rheumatoid arthritis : an observational nationwide study
(
- Contribution to journal › Article
-
Mark
Identifying Predictors of First-Line Subcutaneous TNF-Inhibitor Persistence in Patients with Inflammatory Arthritis : A Decision Tree Analysis by Indication
(
- Contribution to journal › Article
- 2022
-
Mark
Response to : Response to: Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: Is it an overlooked comorbidity?' by Proft et al.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis
(
- Contribution to journal › Article
-
Mark
Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA) : A Retrospective Observational Study
(
- Contribution to journal › Article
- 2021
-
Mark
Pain over 2 years after start of biological versus conventional combination treatment in early rheumatoid arthritis : results from the randomised controlled SWEFOT trial
(
- Contribution to journal › Article
-
Mark
Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care : Does the choice of biological therapy matter?
(
- Contribution to journal › Article
-
Mark
Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis-an inception cohort study
(
- Contribution to journal › Article
-
Mark
Sustained Remission in Patients With Rheumatoid Arthritis Receiving Triple Therapy Compared to Biologic Therapy : A Swedish Nationwide Register Study
(
- Contribution to journal › Article
-
Mark
Chronic Pain and Assessment of Pain Sensitivity in Patients With Axial Spondyloarthritis : Results From the SPARTAKUS Cohort
(
- Contribution to journal › Article
- 2020
-
Mark
Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls : Is it an overlooked comorbidity?
(
- Contribution to journal › Letter
-
Mark
Consultation prevalence among children, adolescents and young adults with pain conditions : A description of age- And gender differences
(
- Contribution to journal › Article
-
Mark
Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients
(
- Contribution to journal › Article
- 2019
-
Mark
Biological treatment of ankylosing spondylitis : A nationwide study of treatment trajectories on a patient level in clinical practice
(
- Contribution to journal › Article
-
Mark
Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis : Results from the SPARTAKUS cohort
(
- Contribution to journal › Article
- 2018
-
Mark
Patient-Reported Outcomes Are More Important Than Objective Inflammatory Markers for Sick Leave in Biologics-Treated Patients With Rheumatoid Arthritis
(
- Contribution to journal › Article
-
Mark
Impact of extra-articular spondyloarthritis manifestations and comorbidities on drug retention of a first TNF-inhibitor in ankylosing spondylitis : A population-based nationwide study
(
- Contribution to journal › Article
- 2017
-
Mark
Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis : Does early anti-TNF therapy bring patients back to work?
(
- Contribution to journal › Article
-
Mark
Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy : A population-based regional cohort study from southern Sweden
(
- Contribution to journal › Article
- 2016
-
Mark
Anti-TNF therapy in rheumatoid arthritis. Effects on and predictors of work disability
(
- Thesis › Doctoral thesis (compilation)
- 2015
-
Mark
Does disease activity at start of biologic therapy influence work-loss in RA patients?
2015) In Rheumatology (Oxford, England)(
- Contribution to journal › Article
- 2014
-
Mark
Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis inception cohort.
(
- Contribution to journal › Article